Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 56, Issue 8, Pages 4471-4473Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00404-12
Keywords
-
Categories
Funding
- European and Developing Countries Clinical Trials Partnership
- Wellcome trust [WT081199/Z/06/Z]
- Wellcome Trust, United Kingdom [WT081199/Z/06/Z, 5374]
Ask authors/readers for more resources
We described the population pharmacokinetics of moxifloxacin and the effect of high-dose intermittent rifapentine in patients with pulmonary tuberculosis who were randomized to a continuation-phase regimen of 400 mg moxifloxacin and 900 mg rifapentine twice weekly or 400 mg moxifloxacin and 1,200 mg rifapentine once weekly. A two-compartment model with transit absorption best described moxifloxacin pharmacokinetics. Although rifapentine increased the clearance of moxifloxacin by 8% during antituberculosis treatment compared to that after treatment completion without rifapentine, it did not result in a clinically significant change in moxifloxacin exposure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available